Literature DB >> 12934968

Neuropathologic changes in Alzheimer's disease.

Gary L Wenk1.   

Abstract

Alzheimer's disease is characterized by degenerative changes in a variety of neurotransmitter systems. These include alterations in the function of the monoaminergic neural systems that release glutamate, norepinephrine, and serotonin as well as a few neuropeptide-containing systems. Alzheimer's disease is also characterized by degenerative changes in selected brain regions, including the temporal and parietal lobes and restricted regions within the frontal cortex and cingulate gyrus. The degeneration of these systems may underlie specific aspects of the dementia associated with Alzheimer's disease. A major problem in Alzheimer's disease research today is that none of the current hypothesized mechanisms are able to explain the cellular and regional distribution pattern that characterizes the neuropathology of Alzheimer's disease. This article summarizes the nature and extent of the changes associated with neural systems, possible treatment approaches, and a potential mechanism involving chronic neuroinflammation to explain the pattern of neuropathologic changes in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934968

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  137 in total

1.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

2.  Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.

Authors:  Aaron Y Lai; Joanne McLaurin
Journal:  Future Neurol       Date:  2012-03-01

Review 3.  Casting a net on dendritic spines: the extracellular matrix and its receptors.

Authors:  Lorraine E Dansie; Iryna M Ethell
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

Review 4.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 5.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 6.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Mass spectrometry imaging, an emerging technology in neuropsychopharmacology.

Authors:  Mohammadreza Shariatgorji; Per Svenningsson; Per E Andrén
Journal:  Neuropsychopharmacology       Date:  2013-08-21       Impact factor: 7.853

Review 8.  Protein carbonylation and metabolic control systems.

Authors:  Jessica M Curtis; Wendy S Hahn; Eric K Long; Joel S Burrill; Edgar A Arriaga; David A Bernlohr
Journal:  Trends Endocrinol Metab       Date:  2012-06-27       Impact factor: 12.015

9.  Crossed Cerebellar Diaschisis in Alzheimer's Disease Detected by Arterial Spin-labelling Perfusion MRI.

Authors:  Alexander Hertel; Holger Wenz; Mansour Al-Zghloul; Lucrezia Hausner; Lutz FrÖlich; Christoph Groden; Alex FÖrster
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 10.  Correlation between MCP-1-2518A/G polymorphism and the risk of Alzheimer's disease.

Authors:  Yan Wang; Siyi Huang; Xiaoling Wu; Yong Wang; Deqi Jiang
Journal:  J Neural Transm (Vienna)       Date:  2018-10-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.